Last reviewed · How we verify

NCT07308860

Fractional Flow Reserve Versus Angiography for Multivessel Evaluation (FAME) 3 Extended

Active, enrolled Last updated 30 December 2025
What this trial tests

trial testing FFR-guided PCI in Coronary Artery Disease in 1,500 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
1 August 2025
Primary endpoint
30 June 2030
30 June 2030

Quick facts

Lead sponsorStanford University
StatusActive, enrolled
Study typeOBSERVATIONAL
Enrollment1,500
Start date1 August 2025
Primary completion30 June 2030
Estimated completion30 June 2030
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Stanford University

Who can join

21 and older, any sex, with Coronary Artery Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Coronary artery disease, or narrowing of the blood vessels that provide blood to the heart, is the most common cause of death in the United States and can be treated with either coronary bypass surgery or coronary stent placement. This study will evaluate outcomes, including death and quality of life, at 10 years in 1,500 patients with coronary disease who have already been randomized to either bypass surgery or stenting.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Coronary Artery Disease

Currently open trials in the same condition.

Other Stanford University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07308860.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing